Costimulatory signals potently modulate the T cell inhibitory capacity of the therapeutic CD11a antibody Efalizumab

Costimulatory signals potently modulate the T cell inhibitory capacity of the therapeutic CD11a antibody Efalizumab

Copyright © 2011 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 139(2011), 2 vom: 15. Mai, Seite 199-207
1. Verfasser: Kuschei, Werner M (VerfasserIn)
Weitere Verfasser: Leitner, Judith, Majdic, Otto, Pickl, Winfried F, Zlabinger, Gerhard J, Grabmeier-Pfistershammer, Katharina, Steinberger, Peter
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2011
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't 4-1BB Ligand Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antigens, CD B7-1 Antigen CD11a Antigen CD28 Antigens CD3 Complex mehr... CD58 Antigens ICOSLG protein, human IL10 protein, human IL4 protein, human Immunoconjugates Immunosuppressive Agents Inducible T-Cell Co-Stimulator Ligand Interleukin-2 Lymphocyte Function-Associated Antigen-1 Intercellular Adhesion Molecule-1 126547-89-5 Interleukin-10 130068-27-8 Interleukin-4 207137-56-2 Abatacept 7D0YB67S97 Interferon-gamma 82115-62-6 efalizumab XX2MN88N5D
LEADER 01000caa a22002652 4500
001 NLM206735642
003 DE-627
005 20250212133952.0
007 cr uuu---uuuuu
008 231224s2011 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2011.02.007  |2 doi 
028 5 2 |a pubmed25n0689.xml 
035 |a (DE-627)NLM206735642 
035 |a (NLM)21414849 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Kuschei, Werner M  |e verfasserin  |4 aut 
245 1 0 |a Costimulatory signals potently modulate the T cell inhibitory capacity of the therapeutic CD11a antibody Efalizumab 
264 1 |c 2011 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 23.06.2011 
500 |a Date Revised 10.12.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2011 Elsevier Inc. All rights reserved. 
520 |a The therapeutic CD11a antibody Efalizumab interferes with psoriasis pathogenesis by blocking T cell activation and migration. We have performed a detailed analysis on its effects during the activation of human T cells and found that the capability of Efalizumab to inhibit proliferation and cytokine production of T cells critically depends on the quality and quantity of costimulatory signals. Efalizumab potently inhibited the proliferation and cytokine production of human T cells costimulated via ICOS, OX40, CD27 or 4-1BB, but did not significantly inhibit T cells that received stimuli via CD2 or CD28. The capacity of CD2 and CD28 signals to interfere with the T cell inhibitory effects of Efalizumab was also observed upon stimulation of T cells with allogeneic DC. Furthermore, studies with T cells from psoriasis patients indicated that Efalizumab therapy induces inhibition of T cell responses that can be reverted by CD2 or CD28 signals 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 7 |a 4-1BB Ligand  |2 NLM 
650 7 |a Antibodies, Monoclonal  |2 NLM 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a Antigens, CD  |2 NLM 
650 7 |a B7-1 Antigen  |2 NLM 
650 7 |a CD11a Antigen  |2 NLM 
650 7 |a CD28 Antigens  |2 NLM 
650 7 |a CD3 Complex  |2 NLM 
650 7 |a CD58 Antigens  |2 NLM 
650 7 |a ICOSLG protein, human  |2 NLM 
650 7 |a IL10 protein, human  |2 NLM 
650 7 |a IL4 protein, human  |2 NLM 
650 7 |a Immunoconjugates  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Inducible T-Cell Co-Stimulator Ligand  |2 NLM 
650 7 |a Interleukin-2  |2 NLM 
650 7 |a Lymphocyte Function-Associated Antigen-1  |2 NLM 
650 7 |a Intercellular Adhesion Molecule-1  |2 NLM 
650 7 |a 126547-89-5  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
650 7 |a Interleukin-4  |2 NLM 
650 7 |a 207137-56-2  |2 NLM 
650 7 |a Abatacept  |2 NLM 
650 7 |a 7D0YB67S97  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
650 7 |a efalizumab  |2 NLM 
650 7 |a XX2MN88N5D  |2 NLM 
700 1 |a Leitner, Judith  |e verfasserin  |4 aut 
700 1 |a Majdic, Otto  |e verfasserin  |4 aut 
700 1 |a Pickl, Winfried F  |e verfasserin  |4 aut 
700 1 |a Zlabinger, Gerhard J  |e verfasserin  |4 aut 
700 1 |a Grabmeier-Pfistershammer, Katharina  |e verfasserin  |4 aut 
700 1 |a Steinberger, Peter  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 139(2011), 2 vom: 15. Mai, Seite 199-207  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:139  |g year:2011  |g number:2  |g day:15  |g month:05  |g pages:199-207 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2011.02.007  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 139  |j 2011  |e 2  |b 15  |c 05  |h 199-207